Low-density and high-density lipoprotein subspecies and risk for premature coronary artery disease

American Journal of Medicine

Volumn 107, Issue 2 SUPPL. 1, 1999, Pages 16-18

  Brunzell, John D ^a   Hokanson, John E ^a  

^a Division of Metabolism Endocrinology and Nutrition   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPROTEIN; CHOLESTEROL; COLESTIPOL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN;

ADULT; ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; BLOOD; INSULIN RESISTANCE; OBESITY; ONSET AGE; REVIEW; RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; ENZYME ACTIVITY; FAMILY HISTORY; HIGH RISK PATIENT; LIPID BLOOD LEVEL; RECEPTOR DENSITY; RISK ASSESSMENT;

AGE OF ONSET; CORONARY DISEASE; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; OBESITY; RISK; RISK FACTORS;

EID: 0032874720     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00139-4     Document Type: Conference Paper

References (25)

1. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med.1988;148:36-69.
2. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
3. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
4. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-1445.
5. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS . JAMA. 279:1998;1615-1622.
6. Sacks F.M., Moye L.A., Davis B.R., et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 97:1998;1446-1452.
7. Mack W.J., Krauss R.M., Hodis H.N. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS) treatment effects and relation to coronary angiographic progression . Arterioscler Thromb Vasc Biol. 16:1996;697-704.
8. Phillips N.R., Waters D., Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 88:1993;2762-2770.
9. Austin M.A., Breslow J.A., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low-density lipoprotein subclass pattern and risk of myocardial infarction. JAMA. 260:1988;1917-1921.
10. Gower B.A., Nagy T.R., Goran M.I., Toth M.J., Poehlman E.T. Fat distribution and plasma lipid-lipoprotein concentrations in pre- and postmenopausal women. Int J Obes Relat Metab Disord. 22:1998;605-611.
11. Crouse J.R., Parks J.S., Schey H.M., Kahl F.R. Studies of low-density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res. 26:1985;566-574.
12. Gardner C.D., Fortmann S.P., Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 276:1996;875-881.
13. Stampfer M.J., Krauss R.M., Ma J., Blanche P.J., Holl L.G., Sacks F.M., Hennekens C.H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:1996;882-888.
14. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men prospective results from the Quebec Cardiovascular Study . Circulation. 95:1997;69-75.
15. Miller B.D., Alderman E.L., Haskell W.L., Fair J.M., Krauss R.M. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 94:1996;2146-2153.
16. Blankenhorn D.H., Alaupovic P., Wickham E., Chin H.P., Azen S.P. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts lipid and nonlipid factors . Circulation. 81:1990;470-476.
17. Hodis H.N., Mack W.J., Azen S.P., et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 90:1994;42-49.
18. Hodis H.N., Mack W.J., Dunn M., Liu C., Selzer R.H., Krauss R.M. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 95:1997;2022-2026.
19. Cheung M.C., Brown B.G., Wolf A.C., Albers J.J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res. 32:1991;383-394.
20. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
21. Maher V.M., Brown B.G., Marcovina S.M., Hillger L.A., Zhao X.-Q., Albers J.J. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 274:1995;1771-1774.
22. Zambon A., Hokanson J.E., Brown B.G., Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression hepatic lipase mediated changes in LDL density . Circulation. 99:1999;1959-1964.
23. Warnick G.R. Measurement and clinical significance of high-density lipoprotein cholesterol subclasses. Rifai N., Warnick G.R., Dominiczak M.H. Handbook of Lipoprotein Testing. 1997;251-256 American Association of Clinical Chemistry Press, Washington, DC.
24. Hokanson J.E., Austin M.A., Brunzell J.D. Measurement and clinical significance of low-density lipoprotein subclasses. Rifai N., Warnick G.R., Dominiczak M.H. Handbook of Lipoprotein Testing. 1998;267-272 American Association of Clinical Chemistry Press, Washington, DC.
25. Brunzell J.D., Hokanson J.E. Dyslipidemia of central obesity and insulin resistance. Diabetes Care. 22:(suppl 3):1999;C10-C13.